A big boost in Q2 with double-digit gains in all segments.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in detail in our comprehensive Q221 US Infection Prevention - Vascular Access Adjunct Products Market Recap* are:

Advanced Wound Care saw a strong recovery against a weak comparator.

For Q221, according to SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up, with all segments showing increases,

The US Wound Biologics market, comprising the vast majority of the global biologics market, includes the very competitive skin substitute or CTP (Cellular and/or Tissue-Based Products) market, the Topical Drug/Delivery category and Collagen Dressings. For Q221, the US market was up significantly, with CTPs accounting for the largest share, driven by Organogensis' substantial YoY gains. 

Among the many topics covered in detail in our comprehensive Q221 Advanced Wound Care Market Recap* are:

Changing market dynamics over the past ten years has not held back the robust Skin Substitute/CTP market.

As SmartTRAK celebrates its 10-year anniversary covering AWC and the Biologics area, we look back at the market drivers, products and players to see how the US Skin Substitute market has changed over the last decade. We also look ahead to see what is in store for the Skin Substitute market, which is projected to reach $1.64B in 2025E.

The following is a preview of our Wound Biologics market retrospective. The full article, available on SmartTRAK, features our industry experts discussing and analyzing these changes and trends in detail.

A return to positive growth for the quarter, but gains lag behind pre-COVID-19 levels.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in detail in our comprehensive Q121 US Infection Prevention - Vascular Access (VA) Adjunct Products Market Recap* are:

Advanced Wound Care begins to stabilize as in-person visits increase and elective procedures rebound.

For Q121, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +6.2%, boosted by a strong performance in Biologics, with 3M maintaining the number one position in the AWC space.

Among the many topics covered in detail in our comprehensive Q121 AWC Market Recap* are:

Procedures using surgical matrices continued their recovery, with breast matrices benefiting more from comparison to the early stages of the pandemic that began last year.

Procedures using surgical matrices resumed their return to pre-COVID levels. The US Surgical Matrices market returned to growth according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie continued to lead the Surgical Matrices market while Becton Dickinson (BD), although still leading the US Hernia Matrices market, continued to slide as the hernia market lagged the recovery in breast matrices.

Among the many topics covered in detail in our comprehensive Q121 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants resumed its growth in Q121 as procedures climbed back towards normal.

While surgical procedures have not fully regained their pre-COVID levels, the US Hemostats and Sealants market grew in Q121 according to SmartTRAK Financial Dashboard. However, it continued to be a tale of two recoveries. CryoLife* and especially JNJ/Ethicon* posted solid gains for the quarter. However, as elective procedures continue to be behind pre-COVID levels, other manufacturers lagged by comparison.

The Symposium on Advanced Wound Care, SAWC, the official meeting of the Wound Healing Society, was held virtually May 10-14 and SmartTRAK attended.

Following is a sampling of some of the takeaways from the meeting that were gathered and curated by our expert analysts and sent out to subscribers in our Daily Updates.

A year of turbulence as COVID-19 affects the WW Advanced Wound Care market at different times and in a variety of ways throughout the year.

For FY20, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was down -1.9% YoY. Q420 grew +1.0%, reflecting the gradual recovery in the market.

Among the many topics covered in the comprehensive Q420/FY20 Advanced Wound Care Market Recap* are:

Anticipated growth for Q4 was weakened by a resurgence of COVID-19 and was not enough to sustain growth with FY20 ending at -3.3% YoY decline.

For FY20, according SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access (VA) Adjunct Products market was down -3.3% YoY, while Q420 revenue was up  +1.2% YoY.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in the comprehensive Q420/FY20 Infection Prevention: US Vascular Access Adjunct Market* are: